<?xml version="1.0" encoding="UTF-8"?> <!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd"> <ArticleSet> <Article> <Journal> <PublisherName>jmedicalcasereports</PublisherName> <JournalTitle>Frontiers in Medical Case Reports</JournalTitle> <PISSN>I</PISSN> <EISSN>S</EISSN> <Volume-Issue>Volume 1; Issue 6</Volume-Issue> <PartNumber/> <IssueTopic>Multidisciplinary</IssueTopic> <IssueLanguage>English</IssueLanguage> <Season>(Nov-Dec, 2020)</Season> <SpecialIssue>N</SpecialIssue> <SupplementaryIssue>N</SupplementaryIssue> <IssueOA>Y</IssueOA> <PubDate> <Year>-0001</Year> <Month>11</Month> <Day>30</Day> </PubDate> <ArticleType>Medical Case Reports</ArticleType> <ArticleTitle>Hepatosplenic T Cell Lymphoma Involved Small Vessels of Central Nervous System</ArticleTitle> <SubTitle/> <ArticleLanguage>English</ArticleLanguage> <ArticleOA>Y</ArticleOA> <FirstPage>1</FirstPage> <LastPage>8</LastPage> <AuthorList> <Author> <FirstName>Jose Armando Justinico</FirstName> <LastName>Castro</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>N</CorrespondingAuthor> <ORCID/> <FirstName>Juan Carlos Arango</FirstName> <LastName>Viana</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> </Author> </AuthorList> <DOI/> <Abstract>Hepatosplenic T-cell lymphoma (HSTCL) is a rare, aggressive type of peripheral T – cell lymphoma characterized by infiltration and proliferation of atypical T-cells within the sinusoids of the spleen, liver, and bone marrow. This case report consists of a young male, who was admitted to a local hospital with a history of unexplained fever, odynophagia, and rash, initially mimicking infectious disease. The patient died due to multiorgan failure and the correct diagnosis only was accomplished in the autopsy. This case highlights the difficulty of diagnosing HSTCL and the necessity of considering it in patients with unknown origin fever with hyperferritinemia.</Abstract> <AbstractLanguage>English</AbstractLanguage> <Keywords>Hepatosplenic T-cell lymphoma,Hyperferritinemia,Central nervous system</Keywords> <URLs> <Abstract>https://www.jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=8551&title=Hepatosplenic T Cell Lymphoma Involved Small Vessels of Central Nervous System</Abstract> </URLs> <References> <ReferencesarticleTitle>References</ReferencesarticleTitle> <ReferencesfirstPage>16</ReferencesfirstPage> <ReferenceslastPage>19</ReferenceslastPage> <References>Foppoli M and Ferreri AJ. Gamma?delta t?cell lymphomas. European journal of haematology 2015; 94: 206-218. Shi Y and Wang E. Hepatosplenic T-Cell Lymphoma: A Clinicopathologic Review with an Emphasis on Diagnostic Differentiation from Other T-Cell/Natural Killer–Cell Neoplasms. Archives of Pathology and Laboratory Medicine 2015; 139: 1173-1180. Yabe M, Miranda RN, Medeiros LJ. Hepatosplenic T-cell Lymphoma: A Review of Clinicopathologic Features, Pathogenesis and Prognostic Factors. Human pathology 2018; 74: 5-16. Vega F, Medeiros LJ, Bueso-Ramos C, Jones D, Lai R, Luthra R, Abruzzo LV. Hepatosplenic gamma/delta T-cell lymphoma in bone marrow: a sinusoidal neoplasm with blastic cytologic features. American journal of clinical pathology 2001; 116: 410-419. Visnyei K, Grossbard ML, Shapira I. Hepatosplenic and;gamma;and;delta; T-cell lymphoma: an overview. Clinical Lymphoma, Myeloma and Leukemia 2013; 13: 360-369. Raza A and Ewton A. Hepatosplenic T-cell lymphoma. Blood 2014; 124: 677-677. Tsunematsu S, Natsuizaka M, Fujita H, Otsuka N, Terashita K, Sato F, Kobayashi T, Nakai M, Tsukuda Y, Horimoto H, Sho T. Hepatosplenic gamma-delta T-cell lymphoma associated with Epstein-Barr virus. Internal Medicine 2014; 53: 2079-2082. Ashmore P, Patel M, Vaughan J, Wiggill T, Willem P, van den Berg E, Philip V, Lakha A. Hepatosplenic T-cell lymphoma: a case series. Hematology/oncology and stem cell therapy 2015; 8: 78-84. Li J, Tian X, Wang M, Liu W, Guo X, Wang K, Nong L, Wang W, Yang Y. a primary retroperitoneal anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor thrombosis. OncoTargets and therapy 2018; 11: 9007. Chauhan A, Garg N, Menias CO, Devine CE, Bhosale PR, Balachandran A. Tumor thrombus as a rare presentation of lymphoma: a case series of 14 patients. American Journal of Roentgenology 2015; 204: W398-W404. Hui M, Uppin SG, Paul TR, Beerappa N. Hepatosplenic T Cell Lymphoma: A Rare Case Report. Indian Journal of Hematology and Blood Transfusion 2014; 30: 17-20. Guo X, Li Q, Zhu YP. Childhood hepatosplenic T-cell lymphoma with skin involvement. Indian Pediatrics 2015; 52: 427-428. Matos DM, Rizzatti EG, Garcia AB, Gallo DA, Falcao RP. Adhesion molecule profiles of B-cell non-Hodgkinand;#39;s lymphomas in the leukemic phase. Brazilian journal of medical and biological research 2006; 39: 1349-1355. Kamel AM, El-Sharkawy NM, Osman RA, Abd El-Fattah EK, El-Noshokaty E, Abd El-Hamid T, Kandeel EZ. Adhesion molecules expression in CLL: Potential impact on clinical and hematological parameters. Journal of the Egyptian National Cancer Institute 2016; 28: 31-37. Setoyama M, Mizoguchi S, Orikawa T, Tashiro M. A case of intravascular malignant lymphomatosis (angiotropic large?cell lymphoma) presenting memory T cell phenotype and its expression of adhesion molecules. The Journal of dermatology 1992; 19: 263-269. Aho R, Ekfors T, Haltia M, Kalimo H. Pathogenesis of primary central nervous system lymphoma: invasion of malignant lymphoid cells into and within the brain parenchyme. Acta neuropathologica 1993; 86: 71-76. Gurion R, Mehta N, Migliacci JC, Zelenetz A, Moskowitz A, Lunning M, Moskowitz C, Hamlin P, Horwitz S. Central nervous system involvement in T-cell lymphoma: A single center experience. Acta Oncologica 2016; 55: 561-566. Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, Pileri S, Ko YH, Cabrera ME, Horwitz S, Kim WS. Peripheral T cell lymphoma, not otherwise specified (PTCL?NOS). A new prognostic model developed by the International T cell Project Network. British journal of haematology 2018; 181: 760-769. Jang YH, Lee SJ, Choi YH, Lee WJ, Kim DW, Kim J, Park TI, Chae YS. Intravascular cytotoxic T-cell lymphoma in a young immunocompetent woman. Annals of dermatology 2014; 26: 496-500. Cerroni L, Massone C, Kutzner H, Mentzel T, Umbert P, Kerl H. Intravascular large T-cell or NK-cell lymphoma: a rare variant of intravascular large cell lymphoma with frequent cytotoxic phenotype and association with Epstein-Barr virus infection. The American journal of surgical Pathology 2008; 32: 891-898. Au WY, Shek WH, Nicholls J, Tse KM, Todd D, Kwong YL. T?cell intravascular lymphomatosis (angiotropic large cell lymphoma): association with Epstein–Barr viral infection. Histopathology 1997; 31: 563-567. Kuo TT, Chen MJ, Kuo MC. Cutaneous intravascular NK-cell lymphoma: report of a rare variant associated with Epstein-Barr virus. The American journal of surgical pathology 2006; 30: 1197-1201. Takahashi E, Kajimoto K, Fukatsu T, Yoshida M, Eimoto T, Nakamura S. Intravascular large T-cell lymphoma: a case report of CD30-positive and ALK-negative anaplastic type with cytotoxic molecule expression. Virchows Archiv 2005; 447: 1000-1006. Zizi-Sermpetzoglou A, Petrakopoulou N, Tepelenis N, Savvaidou V, Vasilakaki T. Intravascular T-cell lymphoma of the vulva, CD30 positive: a case report. European journal of gynaecological oncology 2009; 30: 586-588. Williams G, Foyle A, White D, Greer W, Burrell S, Couban S. Intravascular T?cell lymphoma with bowel involvement: Case report and literature review. American journal of hematology 2005; 78: 207-211. Yabe M, Medeiros LJ, Wang SA, Tang G, Bueso-Ramos CE, Jorgensen JL, Bhagat G, Chen W, Li S, Young KH, Miranda RN. Distinguishing between hepatosplenic T-cell lymphoma and and;gamma;and;delta; T-cell large granular lymphocytic leukemia: a clinicopathologic, immunophenotypic, and molecular analysis. The American journal of surgical pathology 2017; 41: 82-93. Matutes E. Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options. Expert review of hematology 2017; 10: 251-258. Oshimi K. Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias. Internal Medicine 2017; 56: 1759-1769. Nicolae A, Ganapathi KA, Hoc-Tran T, Liqiang X, Torres-Cabala CA, Nanaji NM, Zha HD, Fan Z, Irwin S, Pittaluga S, Raffeld M. EBV-negative Aggressive NK-cell Leukemia/Lymphoma: Clinical, Pathologic, and Genetic Features. The American journal of surgical pathology 2017; 41: 67-74. Gao J, Behdad A, Ji P, Wolniak KL, Frankfurt O, Chen YH. EBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution. Modern Pathology 2017; 30: 1100. Tang YT, Wang D, Luo H, Xiao M, Zhou HS, Liu D, Ling SP, Wang N, Hu XL, Luo Y, Mao X. Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes. Blood cancer journal 2017; 7: 660. Jabbour E, Koscielny S, Sebban C, Peslin N, Patte C, Gargi T, Biron P, Ferme C, Bourhis JH, Vantelon JM, Arnaud P. High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia 2006; 20: 814-819.</References> </References> </Journal> </Article> </ArticleSet>